News

March 16, 2020March 16, 2020

Phase 2 Trial of Probody-Opdivo Combo Expanding in Advanced Cancers

News

An ongoing Phase 1/2a trial exploring a type of engineered antibody — the anti-CTLA-4 probody BMS-986249 by CytomX Therapeutics — alone and in combination with Opdivo (nivolumab) in treating advanced solid tumors is ... Read more

March 11, 2020March 11, 2020

Imfinzi, Alone or in Combo, Fails at Survival Goals in Advanced Bladder Cancer Trial

News

AstraZeneca‘s immune checkpoint inhibitor Imfinzi (durvalumab), used alone or in combination with investigational tremelimumab in Phase 3 trial in newly diagnosed people with inoperable and metastatic bladder cancer, failed to improve overall survival compared ... Read more

March 9, 2020March 9, 2020

1st Patient Dosed in UK Trial of Anti-Cancer Virus TG6002

News

Transgene’s TG6002 has been successfully given to a first person in a Phase 1/2a clinical trial testing it in colorectal cancer patients with inoperable liver metastasis, the company announced. The ... Read more

March 6, 2020March 6, 2020

Cabiralizumab Plus Opdivo Failed to Halt Progression of Advanced Pancreatic Cancer, Trial Shows

News

Combining Five Prime Therapeutics‘ investigational therapy cabiralizumab with Opdivo (nivolumab) — with and without chemotherapy — failed to halt disease progression in people with advanced pancreatic cancer, compared with standard ... Read more

March 5, 2020March 5, 2020

Video: BioNews’ Social Media Campaign Highlights #WhatMakesMeRare

News

In recognition of Rare Disease Day Feb. 29, BioNews Services launched a social media campaign last month asking patients to describe what makes them rare. Running Feb. 7–29, the #WhatMakesMeRare ... Read more

March 4, 2020March 23, 2020

Early Data Support Agenus’ 2 Lead Immunotherapies for Advanced Cervical Cancer

News

Agenus announced early data supporting its two lead immunotherapy candidates — balstilimab and zalifrelimab — for the second-line treatment of advanced cervical cancer that responded poorly to platinum chemotherapy. In ... Read more

March 2, 2020March 2, 2020

Researchers Develop Safer CAR T-cell That Can Be Temporarily Turned ‘Off’

News

Researchers have developed a potentially safer CAR T-cell product — one with a “safety switch” — that can be deactivated in the presence of specific molecules, a new study shows. ... Read more

February 26, 2020March 23, 2020

First Patient Enrolled in Phase 1 Trial Investigating Galinpepimut-S and Opdivo for MPM

News

Investigators enrolled the first patient in a Phase 1 clinical trial to evaluate the effects of the cancer vaccine galinpepimut-S in combination with immune checkpoint inhibitor Opdivo (nivolumab) as a ... Read more

February 24, 2020March 5, 2020

FDA Grants Priority Review to Lurbinectedin for Small Cell Lung Cancer

News

The U.S. Food and Drug Administration (FDA) accepted an application from PharmaMar and Jazz Pharmaceuticals asking for the accelerated approval of lurbinectedin to treat patients with small cell lung cancer ... Read more

February 21, 2020February 21, 2020

Opdivo-Yervoy Combo Showing Durable Benefits in Untreated Kidney Cancers in Long-term Trial

News

A combination of two immune checkpoint inhibitors, Opdivo (nivolumab) and Yervoy (ipilimumab), continues to significantly extend the lives of people newly diagnosed with advanced renal cell carcinoma (RCC) compared to ... Read more